TFF Pharmaceuticals, Inc. (TFFP)
| Previous Close | 6.17 |
| Open | 6.17 |
| Bid | 5.75 x 1100 |
| Ask | 6.06 x 1000 |
| Day's Range | 5.93 - 6.43 |
| 52 Week Range | 3.60 - 9.96 |
| Volume | |
| Avg. Volume | 86,024 |
| Market Cap | 153.439M |
| Beta (5Y Monthly) | 1.76 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.25 |
| Earnings Date | Aug 11, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.00 |
- Motley Fool
TFF Pharmaceuticals, Inc. (TFFP) Q2 2022 Earnings Call Transcript
With me on the line today is Glenn Mattes, president and CEO of TFF; Kirk Coleman, chief financial officer; Dr. Dale Christensen, TFF's director of clinical development; Dr. The press release announcing our second quarter results is available on the TFF Pharmaceuticals website.
- GlobeNewswire
TFF Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
Phase 2 Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder Programs Continue to Advance Expands R&D Operations with New Austin, TX Facility Recent Feasibility Work Confirms Utility of Thin Film Freezing in Developing Next- Generation Vaccines Conference Call and Webcast Scheduled Today, Thursday, August 11, 2022, at 4:30 PM ET FORT WORTH, Texas, Aug. 11, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and
- GlobeNewswire
TFF Pharmaceuticals to Hold Second Quarter 2022 Financial and Business Results Conference Call on August 11, 2022
Company conference call and webcast at 4:30 PM ETFORT WORTH, Texas, Aug. 02, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it will release its financial results and business update for the second quarter of 2022 on Thursday, August 11, 2022, at the close of the U.S. financial mar
